CytRx to Present at the Rodman & Renshaw Global Investment Conference

  CytRx to Present at the Rodman & Renshaw Global Investment Conference

Rodman & Renshaw Global Investment Conference 2013

Business Wire

LOS ANGELES -- September 3, 2013

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development
company specializing in oncology, announces that President and CEO Steven A.
Kriegsman and Vice President of Business Development David J. Haen will
present at the Rodman & Renshaw Global Investment Conference on Monday,
September 9, 2013, at 10:50 a.m. Eastern time (7:50 a.m. Pacific time). The
conference is being held at the Millennium Broadway Hotel in New York City.

A webcast of the presentation will be available on the Company’s website at
http://cytrx.com/investors/presentations.

About the Rodman & Renshaw Global Investment Conference

The 2013 Rodman & Renshaw Global Investment Conference, sponsored by H.C.
Wainwright & Co., LLC, will be held in New York City fromSeptember 8 to 10,
2013at The Millennium Broadway Hotel. More than 200 public & private
companies from around the world are expected to present to an audience of over
1,500 attendees. The conference will feature tracks devoted to
Biotechnology/Healthcare, Technology, Natural Resources, and Growth.

About CytRx Corporation

CytRx Corporation is a biopharmaceutical research and development company
specializing in oncology. The CytRx oncology pipeline is focused on the
clinical development of aldoxorubicin (formerly known as INNO-206), its
improved version of the widely used chemotherapeutic agent doxorubicin. CytRx
is conducting a global Phase 2b clinical trial with aldoxorubicin as a
treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical
trial primarily in the same indication and a Phase 1b study of aldoxorubicin
in combination with doxorubicin in patients with advanced solid tumors, and is
conducting a Phase 1b pharmacokinetics clinical trial in patients with
metastatic solid tumors. The Company plans to initiate a Phase 3 global
pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as
a therapy for patients with soft tissue sarcomas whose tumors have progressed
following treatment with chemotherapy. CytRx also is initiating a Phase 2b
clinical trial with aldoxorubicin in patients with late-stage glioblastoma
(brain cancer). CytRx is expanding its pipeline of oncology candidates based
on a novel linker platform technology that can be utilized with multiple
chemotherapeutic agents and could allow for greater concentration of drug at
tumor sites. The Company also has rights to two additional drug candidates,
tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the
ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia
(B-CLL), plans to seek a partner for further development of bafetinib, and is
evaluating further development of tamibarotene. For more information about
CytRx Corporation, visit www.cytrx.com.

Contact:

Investor Relations:
Legend Securities, Inc.
John M. Columbia, 718-233-2677
jcolumbia@legendsecurities.com
or
CytRx Corporation
David J. Haen, 310-826-5648 x304
Vice President, Business Development
dhaen@cytrx.com
 
Press spacebar to pause and continue. Press esc to stop.